Withdrawals due to adverse events · patients with iliotibial band friction syndrome (knee tendinitis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Withdrawals due to adverse events · participants with rheumatoid arthritis and with partial response to MTX
The intervention showed no clear difference in withdrawals due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · participants with rheumatoid arthritis and with a partial response to DMARDs
The intervention showed no clear difference in withdrawals due to adverse events (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in withdrawals due to Adverse events compared with placebo + MTX/DMARD (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review
Withdrawals due to adverse events · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Withdrawals due to adverse events · adult men with premature ejaculation
SSRI may leads to higher study withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in study withdrawals due to adverse events compared with skim milk, plus lactose powder (low certainty).
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Withdrawals due to adverse events · atopic eczema
1 finding from 1 review
Withdrawals due to adverse events · atopic eczema
1 finding from 1 review
Withdrawals due to adverse events · men with sexual dysfunction
It is very uncertain whether testosterone changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
2 findings from 1 review
Withdrawals due to adverse events · men with sexual dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · men with sexual dysfunction
Testosterone as an add‐on to PDE5I showed no clear difference in treatment withdrawal due to adverse events compared with PDE5I alone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with drug‐resistant epilepsy
1 finding from 1 review
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in withdrawals due to adverse events 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review